webinar register page

Webinar banner
The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding
The use of direct oral anticoagulants for stroke prevention in atrial fibrillation continues to rise. Certain populations may be at higher risk for increased drug exposure and adverse events. Pharmacokinetic studies suggest increased exposure of rivaroxaban and apixaban with combined P-gp and moderate CYP3A4 inhibitors but the clinical relevance of this is unknown. This retrospective cohort study included patients receiving rivaroxaban or apixaban from January 1, 2012 to December 31, 2016 with a moderate inhibitor (amiodarone, dronedarone, diltiazem, verapamil) for at least 3 months in the drug-drug interaction (DDI) group.

This webinar will discuss the results of this trial, and how it should inform your practice.

We are pleased to have the following expert speakers join us for this webinar:
Sarah Hanigan, PharmD
Sara Vazquez, PharmD, BCPS, CACP
Tracy Minichiello, MD
Geoffrey Barnes, MD, MSc, FACC, FAHA, FSVM
Diane Wirth, RN, MSN, ANP-BC, CACP

Feb 27, 2020 12:00 PM in Eastern Time (US and Canada)

* Required information


Sarah Hanigan, PharmD
Clinical Pharmacist @University of Michigan Health System
Her practice areas include general cardiology, advanced heart failure/transplant, and cardiac critical care. Her areas of research interest include anticoagulation, heart failure/transplant and quality improvement.